Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Go back to Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 85.97 -0.81 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.78 | 52 Week High | $8.22 | |||
| Open | $86.84 | 52 Week Low | $3.07 | |||
| Day High | $87.50 | P/E | N/A | |||
| Day Low | $85.54 | EPS | $-1.30 | |||
| Volume | 1,160,589 | |||||
